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Abstract
CD133 (prominin-1), a 5-transmembrane glycoprotein, has recently been considered to be an important marker that
represents the subset population of cancer stem-like cells. Herein we report the isolation of CD133-positive cells (LC-
CD133
+) and CD133-negative cells (LC-CD133
2) from tissue samples of ten patients with non-small cell lung cancer (LC) and
five LC cell lines. LC-CD133
+ displayed higher Oct-4 expressions with the ability to self-renew and may represent a reservoir
with proliferative potential for generating lung cancer cells. Furthermore, LC-CD133
+, unlike LC-CD133
2, highly co-
expressed the multiple drug-resistant marker ABCG2 and showed significant resistance to chemotherapy agents (i.e.,
cisplatin, etoposide, doxorubicin, and paclitaxel) and radiotherapy. The treatment of Oct-4 siRNA with lentiviral vector can
specifically block the capability of LC-CD133
+ to form spheres and can further facilitate LC-CD133
+ to differentiate into LC-
CD133
2. In addition, knock-down of Oct-4 expression in LC-CD133
+ can significantly inhibit the abilities of tumor invasion
and colony formation, and increase apoptotic activities of caspase 3 and poly (ADP-ribose) polymerase (PARP). Finally, in
vitro and in vivo studies further confirm that the treatment effect of chemoradiotherapy for LC-CD133
+ can be improved by
the treatment of Oct-4 siRNA. In conclusion, we demonstrated that Oct-4 expression plays a crucial role in maintaining the
self-renewing, cancer stem-like, and chemoradioresistant properties of LC-CD133
+. Future research is warranted regarding
the up-regulated expression of Oct-4 in LC-CD133
+ and malignant lung cancer.
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Introduction
Lung cancer is one of the leading causes of cancer-related
deaths in industrialized countries [1,2]. Radiotherapy and
chemotherapy play significant and crucial roles in clinical anti-
lung cancer treatment to achieve prolonged patient survival [3,4].
However, a high failure rate and low median survival rate are
observed in patients undergoing chemoradiotherapy with recur-
rent, intractable lung cancer [5]. To improve the patient survival
rate, investigation to elucidate the mechanism of tumorigenesis of
lung cancer is needed [5]. Recent data have demonstrated that
tumors contain a small subpopulation of cells, i.e., cancer stem-like
cells (CSCs) or cancer-initiating cells (CICs), which exhibit a self-
renewing capacity and are responsible for tumor maintenance and
metastasis [6]. Stem cells have been isolated by their ability to
efflux Hoechst 33342 dye and are referred to as the ‘‘side
population (SP)’’ [7]. Ho and colleagues isolated and characterized
SP cells from six human lung cancer cell lines and showed that an
elevated expression of ABCG2 as well as other ATP-binding
cassette transporters were positively correlated with resistance to
multiple chemotherapeutic drugs [8]. In addition, Gutova and
colleagues have purified uPAR-positive CSCs from three lung
cancer cell lines. These uPAR-positive cells co-expressed with
CD44 and MDR1, and had the ability to promote advanced
malignancy and chemoresistance [9].
CD133 (prominin-1), a 5-transmembrane glycoprotein, was first
recognized in CD34
+ progenitor populations from adult blood,
bone marrow, and fetal liver cells [10]. Recently, CD133 has been
considered an important marker to represent the subset population
of CSCs in leukemia, brain tumors, retinoblastoma, renal tumors,
pancreatic tumors, colon carcinoma, prostate carcinoma, and
hepatocellular carcinoma [11–19]. Based on immunohistochem-
ical findings, Hilbe and colleagues suggested that CD133-positive
(CD133
+) progenitor cells play a role in the development of tumor
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[20]. More recently, a well-designed study by Eramo and
colleagues showed that lung cancer contains a population of
CD133
+ CSCs able to self-renew and generate an unlimited
progeny of non-tumorigenic cells. These CD133
+ cells are also
resistant to conventional chemotherapy [21]. However, the gene
regulation mechanisms in maintaining the self-renewal and drug-
resistant properties in putative cancer stem-like cells of lung
tumors are still unclear.
Oct-4, a member of the family of POU-domain transcription
factors, is expressed in pluripotent embryonic stem (ES) and germ
cells [22–23]. Oct-4 mRNA is normally found in totipotent and
pluripotent stem cells of pregastrulation embryos [24]. Knocking
out the Oct-4 gene in mice causes early lethality due to the lack of
ICM formation, indicating that Oct-4 has a critical function for
self-renewal of ES cells [25]. Oct-4 activates transcription via
octamer motifs, and Oct-4 binding sites have been found in
various genes, including fgf 4 (fibroblast growth factor 4) and pdgfar
(platelet-derived growth factor a receptor) [26,27]. This suggests
that Oct-4 functions as a master switch during differentiation by
regulating the pluripotent potentials of the stem cell, and Oct-4
plays a pivotal role in mammalian development [24,25].
In this study, the CD133-positive cells (LC-CD133
+) and
CD133-negative cells (LC-CD133
2) were isolated from tissue
samples of lung cancer (LC) patients and LC cell lines. These LC-
CD133
+ cells possessed both the characteristics of stem-like cells
and malignant tumors. Our data further demonstrated that Oct-4
expression in LC-CD133
+ is involved in tumor malignancy of lung
cancers and exhibits refractory properties for chemoradiotherapy
in cancer stem-like cells. These results suggested that the
expression of Oct-4 plays a crucial role in maintaining cancer
stem-like and chemoradioresistant properties in lung cancer-
derived CD133
+ cells.
Materials and Methods
Isolation of CD133
+ Cell Subset
This research followed the tenets of the Declaration of Helsinki
and all samples were obtained after patients provided informed
consent. The study was approved by the Institutional Ethics
Committee/Institutional Review Board of Taipei Veterans
General Hospital. The dissociated cells from the samples of non-
small cell lung cancer patients (Table 1) and the lung cancer (LC)
cell lines were labeled with 1 mL CD133/l micromagnetic beads
per 1 million cells using the CD133 cell isolation kit (Miltenyi
Biotech, Auburn, CA). CD133
+ cells were cultured in a medium
consisting of serum-free DMEM/F12 (Gibco-BRL, Gaithersburg,
MD), N2 supplement (R&D Systems Inc., Minneapolis), 10 ng/ml
human recombinant bFGF (R&D Systems) and 10 ng/ml EGF
(R&D Systems) [28].
Cell Viability Determined by Colorimetric Assay
The isolated CD133
+ and CD133
2 cells were cultured in a 96-
well cell culture cluster (Corning Costar, Acton, MA) at a density
of 3610
3 cells/well with 100 ml culture medium. At specific time
points during cultivation, the medium was discarded and replaced
with an equal volume (100 ml) of fresh medium containing
0.2 mg/ml of 3- (4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS, Promega, Madi-
son, WI) and 0.038 mg/ml of phenazine methosulfate (PMS;
Promega) and incubated for additional 1.5 hours in 37uC5 %
CO2. Cell viability proportionate to optical density (OD) was
measured by colorimetric assay in terms of mitochondria activity
to convert tetrazolium salt into a colored soluble formazan product
in the medium. The OD values were measured at the wavelength
of 490 nm with a 1420 multilabel counter VICTOR from Wallac
(PerkinElmer Wallac, Turku, Finland).
Real-time Reverse Transcription-polymerase Chain
Reaction (RT-PCR)
For real-time RT-PCR analysis, the total RNA of cells was
extracted by using the RNAeasy kit (Qiagen, Valencia, CA). Briefly,
the total RNA (1 mg) of each sample was reversely transcribed in
20 mL using 0.5 mg of oligo dT and 200 U Superscript II RT
(Invitrogen, Carlsbad, CA). The amplification was carried out in a
total volume of 20 ml containing 0.5 mM of each primer, 4 mM
Table 1. The tumor formation abilities of CD133
+ and
CD133
2 in NSCLC description and tumorigenic characteristics
of CD133
+
Tumor formation
No. Type Staging/TNM
CD133+
(%) SF CD133+ CD1332
1 AC IIIB pT4pN3pMX 5.9 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
2 AC IIIA pT2pN2pMX 2.6 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
3 AC IIA pT1pN1pMX 0.7 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(1/3) 1,000(0/3)
4 AC IIB pT3pN0pMX 1.4 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
5 AC IIB pT2pN1pMX 0.5 Yes 10,000(3/3) 10,000(0/3)
3,000(2/3) 3,000(0/3)
1,000(1/3) 1,000(0/3)
6 AC IIIA pT3pN1pMX 0.7 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(1/3) 1,000(0/3)
7 AC IIIB pT3pN3pMX 3.7 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
8 SCC IA pT1pN0pMX 0.3 Yes 10,000(3/3) 10,000(0/3)
3,000(2/3) 3,000(0/3)
1,000(0/3) 1,000(0/3)
9 SCC IIIA pT3pN2pMX 2.3 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(2/3) 1,000(0/3)
10 SCC IIIA pT2pN2pMX 1.1 Yes 10,000(3/3) 10,000(0/3)
3,000(3/3) 3,000(0/3)
1,000(3/3) 1,000(0/3)
CD133
+ and CD133
2 cells were injected into the tail vein of SCID mice,
respectively. NSCLC: non-small cell lung cancer. SF: sphere formation. AC:
adenocarcinoma. SCC: squamous cell carcinoma. Positive response (Positivity):
the tumor formation in the lung tissues of SCID mice. Sphere Formation: Under
serum-free medium with bFGF & EGF culture for 4 weeks.
doi:10.1371/journal.pone.0002637.t001
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(Roche Diagnostics, Pleasanton, CA) and 2 ml of 1:10 diluted
cDNA. The quantification of the unknown samples was performed
by LightCycler Relative Quantification Software, version 3.3
(Roche Diagnostics). In each experiment, the GAPDH house-
keeping gene was amplified as a reference standard. GAPDH
primers were designed: GAPDH(f): GCCAAAAGGGTCAT-
CATC (nt 448–465, GenBank accession no. NM_002046),
GAPDH(r): ATGACCTTGCCCACA GCCTT (nt 745–765),
Oct-4a(f): CGCAAGCCCTCATTTCAC (nt 5–22, GenBank
accession no. NM_002701), Oct-4a(r): CATCACCTCCAC-
CACCTG (nt 98–115, GenBank accession no. NM_002701).
PCR reactions were prepared in duplicate and heated to 95uC for
10 minutes followed by 40 cycles of denaturation at 95uC for
10 seconds, annealing at 55uC for 5 seconds, and extension at
72uC for 20 seconds. All PCR reactions were performed in
duplicate. Standard curves (cycle threshold values versus template
concentration) were prepared for each target gene and for the
endogenous reference (GAPDH) in each sample.
Immunofluorescence Staining for Stem Cell Markers
An avidin-biotin complex method was used for the immuno-
fluorescence staining in the differentiated spheroid and neuronal-
like cell. In brief, cells were plated onto poly-L-ornithine-coated
glass coverslips and fixed with 4% paraformaldehyde for 15 to
20 minutes at room temperature, and then were washed twice
(10 minutes each) with 16 PBS. Cells were permeabilized with
0.1% Triton X-100/PBS for 10 minutes at room temperature,
and then twice (10 minutes each) with 16 PBS. The cells were
then blocked with blocking solution for 30 minutes and were
incubated with primary antibodies (Oct-4, Chemicon, Temecula,
CA) for 1 hour at room temperature. We then washed the cells
three times (10 minutes each) with 16 PBS. Immunoreactive
signals were detected with a mixture of biotinylated rabbit
antimouse IgG and Fluorsave (Calbiochem, San Diego, CA).
Cells were further probed with fluorescein isothiocyanate (FITC)-
tagged secondary antibodies. Fluorescence images were visualized
with a fluorescence microscope. To quantitatively analyze the
fluorescence intensity, we recorded images with an inverted
fluorescence microscope equipped with a CCD camera. The
percentage of signal fluorescence per photographed field was
analyzed by image processing software (Image Pro-Plus, Media-
Cybernetics, Inc., Silver Spring, MD).
FACS Analysis
For cell surface marker identification, a single cell suspension of
sixth- to eighth-passage cells from trypsinized spheres was stained
with anti-CD133, CD117 (c-Kit), or ABCG2 and secondary
fluorescein (FITC)-or phycoerythrin (PE)-coupled antibodies
(Dako, Carpinteria). Cells were fixed with 2% paraformaldehyde
and were analyzed with a BD FACSCalibur apparatus (Becton,
Dickinson and Company, Franklin Lakes, NJ).
Radiation Treatment for Cell Viability Analysis
The gamma radiation (ionizing irradiation; IR) was delivered by
a Theratronic cobalt unit T-1000 (Theratronic International, Inc.,
Ottawa, Canada) at a dose rate of 1.1Gy/min (SSD=57.5cm). To
evaluate the cell proliferation rate we seeded cells on 24-well plates
at a density of 2610
4 cells/well. Cells were seeded 24 hours after
IR and then they were analyzed by methyle thiazol tetrazolium
assay (MTT assay, Sigma-Aldrich, St. Louis, MN). The amount of
MTT formazon product was determined by using a microplate
reader and the absorbance was measured at 560 nm (SpectraMax
250, Molecular Devices, Sunnyvale, CA).
Chemotherapeutic Agents
Cisplatin, etoposide (VP16), and paclitaxel were obtained from
Sigma-Aldrich and were dissolved in DMSO (Sigma-Aldrich) at
100 mM of stock solution.
In Vitro Cell Invasion Analysis and Soft Agar Colony Assay
The 24-well plate Transwell system with an 8-mmp o r es i z e
polycarbonate filter membrane (Corning Costar, Corning, NY) was
used. The filter membrane was coated with Matrigel (BD
Biosciences, San Diego) diluted with serum-free medium and
incubated overnight at 37uC. The cell suspensions were seeded to
the upper compartment of the Transwell chamber at the cell density
of 1610
5 in 100 ml serum free medium. After 24 hours, the medium
was removed and the filter membrane was fixed with 4% formalin
for 1 hour. The opposite surface of the filter membrane facing the
lower chamber was stained with Hoechst 33342 (Sigma-Aldrich) for
3 minutes and the migrated cells were then visualized under an
inverted microscope. The protocol of soft agar colony assay is
described as follows. Each well (35 mm) of a six-well culture dish was
coated with 2 ml bottom agar mixture (DMEM, 10% (v/v) FCS,
0.6% (w/v) agar). After the bottom layer solidified, 2 ml top agar-
medium mixture (DMEM, 10% (v/v) FCS, 0.3% (w/v) agar)
containing 2610
4 cells was added, and the dishes were incubated at
37uC for 4 weeks. Plates were stained with 0.5 ml of 0.005% crystal
violet for 1 hour and then a dissecting microscope was used to count
the number of colonies [29].
Lentiviral-mediated RNAi
The pLVRNAi vector and pCDH-MCS1-EF1-copGFP vector
were purchased from Biosettia Inc. (Biosettia, San Diego, CA). The
method of cloning the double-stranded shRNA sequence is
described in the manufacturer’s protocol. The siRNA oligonucleo-
tide 59-CCGGCCCTCACTTCACTGCACTGTACTCGAGTA-
CAGTGC AGTGAAGTGAGGGTTTTT-39 targeting human
Oct-4 (NM_002701, nt 1035-1055) was synthesized and cloned into
pLVRNAi to generate a lentiviral expression vector. The Oct-4
cDNA was amplified and purified by RT-PCR and cloned into a
pCDH-MCS1-EF1-copGFP vector. Lentiviral production was done
by transfection of 293T cells using Lipofectamine 2000 (LF2000,
Invitrogen). Supernatants were collected 48 hours after transfection
and then were filtered; the viral titers were then determined by
FACS at 48 hours post-transduction. Subconfluent cells were
infected with lentivirus at a multiplicity of infection of 5 in the
presence of 8 ı `g/ml polybrene (Sigma-Aldrich).
In Vivo Analysis of Tumor Growth and Metastasis
All procedures involving animals were in accordance with the
institutional animal welfare guidelines of Taipei Veterans General
Hospital. 1000, 3000, and 10
4 cells were injected into the tail vein
of SCID mice and/or nude mice (BALB/c strain) each aged
8 weeks. In vivo GFP imaging was visualized and measured by an
illuminating device (LT-9500 Illumatool TLS equipped with
excitation illuminating source [470 nm] and filter plate [515 nm]).
The tumor size was measured with calipers and the tumor volume
was calculated according to the formula (Length6Width
2)/2. The
integrated optical density of green fluorescence intensity was
captured and then analyzed by Image Pro-plus software [29].
Statistical Analysis
Statistical Package of Social Sciences software (version 13.0)
(SPSS, Inc., Chicago, IL) was used for statistical analysis. The
independent Student’s t-test or ANOVA was used to compare the
continuous variables between groups, whereas the x
2 test was
OCT4 in CD133 Lung Cancer Cell
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Meier estimate was used for survival analysis, and the log-rank test
was used to compare the cumulative survival durations in different
patient groups. The level of statistical significance was set at 0.05
for all tests.
Results
Isolation and Characterization of Lung Cancer-derived
CD133-positive Cells
Using the magnetic bead method, we isolated CD133
+ cells
(Fig. 1A) from tissue samples of ten non-small cell lung cancer
(NSCLC) patients (Table 1) and five lung cancer (LC) cell lines
(Table S1). The high percentage (97%) of CD133
+ (LC-CD133
+)
subset was isolated in the LC tissues and parental LC cell line
(Fig. 1A). It has been reported that cancer stem-like cells can be
cultured in suspension to generate floating spheroid-like bodies
(SB) under serum-free medium with bFGF & EGF [30]. We found
that LC-CD133
+ isolated from these ten patients (Table 1) and five
LC cell lines (Table S1) can form SB in DF-12 serum-free medium
with bFGF and EGF (Fig. 1B; No.1 [PLC] and No.2 [LLC]).
Furthermore, the ability to form SB (Fig. 1C) and proliferation rate
(Fig. 1D) in LC-CD133
+ were significantly higher than that in LC-
CD133
2 (p,0.05). In addition, to determine the in vivo
tumorigenic activity of LC-CD133
+ and LC-CD133
2, we injected
respective amounts of 1000, 3000, and 10
4 cells into the tail veins
of SCID mice. The results showed that 10
4 LC-CD133
2 did not
induce tumor formation but 3,000 LC-CD133
+ from the lung
cancer tissues of ten patients and five LC cell lines in
xenotransplanted mice can all generate visible tumors 4 weeks
after injection (Table 1 and Table S1).
Increased ABCG2 Expression and Invasive Ability of LC-
CD133
+ In Vitro
To characterize our isolated LC-CD133
+, FACS analysis was
used to detect the expression profile of cells surface markers. As
shown in Figure 2A, the majority of isolated LC-CD133
+ were
stained with higher expression levels of CD133, CD117 (c-Kit), and
ABCG2 compared with LC-CD133
2. This result demonstrated that
isolated LC-CD133
+ werealmostABCG2-positive cells (Fig. 2B).To
further evaluate the enhancement of tumorigenicity of LC-CD133
+,
we examined in vitro Matrigel-combined Transwell invasion and soft
agar colony formation assays. Compared with LC-CD133
2,L C -
CD133
+ derived from NSCLC Patients No.1 (PLC) and No. 2
(LLC) showed higher invasion activity through Matrigel Transwell
invasion assay (p,0.001; Fig. 2C). Similarly, the foci formation
ability of LC-CD133
+ from PLC (No.1) and LLC (No.2) was
enhanced when compared with the LC-CD133
2 of those two
patients (p,0.001; Fig. 2D).
Increased In Vivo Tumor-restoration and Proliferative
Ability in LC-CD133
+
We further evaluated the in vivo tumor-restoration and
proliferative ability of LC-CD133
+ and LC-CD133
2 by xeno-
transplanted tumorigenicity analysis (Fig. 3A). Four weeks after
10
4 cells were injected into the tail veins of SCID mice, a
significant increase in the multiple nodules of tumor formation on
lung surface was noted in the LC-CD133
+-injected group
(Figs. 3A4 & 3A7) but not in the LC-CD133
2 group (Fig. 3A1).
Diffuse infiltrations of LC-CD133
+ from the lung parenchyma to
the alveolar cavity were observed (Figs. 3A5, 3A6, and 3A8). The
histological examination demonstrated that the prominent neo-
vascularization and thrombus formation were detected in the
pulmonary parenchyma of LC-CD133
+-injected SCID mice
(Fig. 3A9). In contrast, no significant tumor foci or neovascular
formation was found in the lungs of LC-CD133
2-injected SCID
mice (Figs. 3A2 & 3A3). We further investigated the in vivo tumor
growth rate in 10
4 LC-CD133
+ cells, 10
6 LC-CD133
2 cells, and
5610
6 parent tumor cells from the same patient. The finding
demonstrated that the tumor growth rate of the 10
4 LC-CD133
+
group (from Patients No. 1, 2, 4, and 7; Table 1) was significantly
higher than that of the 10
6 LC-CD133
2 group and 5610
6
parental tumor cell group (Fig. 3B). Furthermore, 10
4 LC-CD133
+
isolated from secondary tumors can further generate new (second)
tumors from transplanted SCID mice. Results of flow cytometry
showed that a high percentage (60%) of CD133-positive cells was
detected in the second tumor (Fig. 3C). In addition, one thousand
LC-CD133
+ isolated from the second tumor can also generate a
new (third) tumor in transplanted SCID mice (Fig. 3C). To sum,
our data indicated that LC-CD133
+ present self-renewing and
repopulation capabilities both in vitro and in vivo.
Enhanced Chemo- and Radiation-resistance in LC-
CD133
+
We evaluated the multidrug (chemotherapy)-resistant abilities of
LC-CD133
+ and LC-CD133
2. We further tested four common
chemotherapeutic agents including cisplatin, VP16 (etoposide),
doxorubicin, paclitaxel. Compared with LC-CD133
2, LC-
CD133
+ are significantly resistant to the four tested chemother-
apeutic agents (p,0.01; Fig. 4A). To further determine the
radiation effect on the rate of tumor growth, we used an ionizing
radiation (IR) dose from 0 to 10 Gy to treat both LC-CD133
+ and
LC-CD133
2. As shown in Fig. 3B, after IR treatment, the survival
rate and number of LC-CD133
+ were significantly higher than
those of LC-CD133
2 (p,0.01). We further found that the LC-
CD133
+ cells possess a higher degree of radioresistance (p,0.01;
Fig. 4B). Moreover, we investigated the combined treatment effect
of radiochemotherapy in LC-CD133
+. Experiments were con-
ducted with cisplatin (10 mM) alone, VP-16 (10 mM) alone, or
combined cisplatin and VP-16 on IR (2 Gy)-treated LC-CD133
+.
As shown in Figure 3C, the data revealed that the cell survival rate
in IR-treated LC-CD133
+ was not significantly decreased by the
IR treatment combined with cisplatin, with or without VP-16
(p.0.05). On the contrary, cell survival significantly declined after
chemotherapy with cisplatin combined with VP-16 in IR-treated
LC-CD133
2 (p,0.01; Fig. 4C). These results suggest that LC-
CD133
+ may play a vital role in the tumor’s ability to resist
radiation and chemotherapies.
Role of Oct-4 Expression in LC-CD133
+
Microarray results suggested that the expression level of Oct-4
self-renewal and stemness gene in LC-CD133
+ was significantly
up-regulated than that in LC-CD133
2. To validate this finding,
we examined expression of Oct-4 both transcriptionally and
translationally. The amounts of Oct-4 transcript and protein of
isolated LC-CD133
+ (Patients No.1 [PLC] and No.2 [LLC]) were
significantly increased compared with those of LC-CD133
2 by
real-time RT-PCR and western blotting analysis (Figs. 5A and 5B).
To investigate whether Oct-4 expression plays a role in
maintaining self-renewal or cancer stem-like properties in LC-
CD133
+, we used the siRNA method with lentiviral vector for
knockdown of Oct-4 expression in LC-CD133
+. We found it
important that the treatment of Oct-4 siRNA in LC-CD133
+ can
significantly interfere with the capabilities of spheroid-like bodies
(SB) formation (p,0.001; Fig. 5C). After 7 days of the Oct-4
siRNA treatment, the SB of LC-CD133
+ could not maintain
floating spheres but differentiated into attached epithelial-like cells
OCT4 in CD133 Lung Cancer Cell
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+ (LC-CD133
+). (A) Using a magnetic bead method, we sorted
CD133
+ cells from tissue samples of patients with lung cancer (LC), and characterized them by FACS assay. (B) LC-CD133
+ sorted from two patient
with No.1 (PLC-CD133
+) and No.2 (LLC-CD133
+) were cultured in bFGF and EGF with DMEM serum-free medium. (C) Evaluation of the formation
abilities of spheroid-like bodies (SB) from LC-CD133
+ and LC-CD133
2 under serum-free medium with bFGF & EGF. (D) The growth curves of LC-
CD133
+ and LC-CD133
2 were measured by hemocytometer. Bar: 100 mm. Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g001
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not influence the SB formation capability in LC-CD133
+ (Fig. 5C).
The SB of LC-CD133
+ endogenously expressed strong positive
signals for Oct-4 and CD133 (Fig. 5D). Furthermore, the
immunofluorescent results demonstrated that both the CD133
and Oct-4 expressions in LC-CD133
+ were significantly blocked
after 7 days of Oct-4 siRNA treatment (Fig. 5D). FASC assay
confirmed that the amount of CD133 was dramatically decreased
in Oct-4 siRNA-treated LC-CD133
+ and the percentages of LC-
CD133
2 were significantly increased in LC-CD133
+ after 7 days
of Oct-4 siRNA treatment (p,0.001; Fig. 5E). These data
suggested that Oct-4 may maintain the properties of primitive
stem cells and inhibit the tendency for differentiation in LC-
CD133
+.
Enhanced Chemoradiotherapeutic Sensitivity and
Apoptotic Activity in LC-CD133
+ Treated by Oct-4 siRNA
To further study the role of Oct-4 in tumor malignancy of LC-
CD133
+ in vitro, the migration/invasive and soft agar colony assay
were used. The results showed that the abilities of the in vitro
migratory invasion and colony formation in LC-CD133
+ treated
by Oct-4 siRNA were significantly decreased compared with non-
treated LC-CD133
+, or LC-CD133
+ treated with scramble-siRNA
(control; p,0.001; Fig. 6A). Furthermore, the treatment effect of
chemoradiotherapy for the LC-CD133
+ group can be significantly
improved by the treatment of Oct-4 siRNA compared with non-
treated LC-CD133
+ or LC-CD133
+ treated by scramble-siRNA
(Fig. 6B; p,0.001). In addition, we found that the apoptotic
activities of annexin V (Fig. 6C) and caspase 3 (Fig. 6D; upper
Figure 2. Detection of surface markers and the tumorigenicity in LC-CD133
+ and LC-CD133
2 in vitro. (A) and (B) The expression levels of
CD133, CD117 (c-Kit), and ABCG2 were analyzed by FACS assay in LC-CD133
+ and LC-CD133
2. The capabilities of (C) the migration/invasion and (D)
the tumor foci (soft agar colony) formation in LC-CD133
+ were significantly increased compared with LC-CD133
2 (*p,0.001). Data shown here are
the mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g002
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+ treated
by Oct-4 siRNA after 72 hours. In accordance with the result of cell
survival and treatment effects in Oct-4 siRNA-treated LC-CD133
+
(Fig. 6B), the western blot data further demonstrated that the
amounts of activated (cleaved) form of PARP were consistently
elevated in LC-CD133
+ treated by Oct-4 siRNA with IR alone or
combined with chemotherapy (Fig. 6D; lower part). Thus,
knockdown of Oct-4 expression in LC-CD133
+ can effectively
enhance chemoradiosensitivities and apoptotic activities in response
to IR and chemotherapy, suggesting that Oct-4 could be a key factor
enables LC-CD133
+ to resist radiochemotherapeutic stress.
Inhibition of In Vivo Tumorgeneic Potential in Oct-4
siRNA-treated LC-CD133
+
To investigate the treatment effects of chemoradiotherapy on
Oct-4 siRNA-treated LC-CD133
+, LC-CD133
+ was first trans-
fected by lentivector combined with green fluorescent protein gene
(GFP), and then in vivo GFP imaging and histological study were
used to monitor the tumor-growth effect. We first injected 10
4 LC-
CD133
+-GFP cells into the subcutaneous sites of nude mice with
different treatment protocols. The tumor volumes were signifi-
cantly decreased in Oct-4 siRNA-treated LC-CD133
+ when
exposed to IR alone, cisplatin alone, or IR combined with
cisplatin (p,0.01; Fig. 7A). To further evaluate the capabilities of
tumor invasion and metastasis of LC-CD133
+ treated by different
regimens, we injected 10
4 LC-CD133
+-GFP cells from each
treatment groups into the tail vein of SCID mice. The results of in
vivo GFP imaging showed that the tumor foci of lung and
metastatic lesions in the Oct-4-siRNA-treated LC-CD133
+ groups
were significantly lower than those of the LC-CD133
+ without
Oct-4-siRNA-treated groups (p,0.01; Fig. 7B). In addition, to
investigate the treatment effects of Oct-4 expression in LC-
CD133
+ in vivo, we injected the seven groups with different
regimens individually into the tail vein of SCID mice for
xenotransplanted tumorigenicity analysis (Fig. 7C). Immunohisto-
chemistry (IHC) showed that the expression levels of Oct-4 in the
lung tumors of LC-CD133
+-injected SCID mice were highly
expressed in comparison with the other treated-groups (Fig. 7C).
Oct-4-IHC levels were significantly decreased in Oct-4 siRNA-
treated LC-CD133
+ when exposed to IR alone, cisplatin alone, or
IR combined with cisplatin (p,0.01; Fig. 7C). Moreover, using
combined chemoradiotherapy with the treatment of Oct-4 siRNA,
the mean survival rate of the LC-CD133
+ group was significantly
prolonged compared with the control or other treated groups
(p,0.05; Fig. 7D). This in vivo study also confirmed that the
treatment effect of chemoradiotherapy for the LC-CD133
+ group
can be improved by the treatment of Oct-4 siRNA.
Discussion
Self-renewal and pluripotency are the central features in the
definition of embryonic stem cells (ESC), and Oct-4 is a key
regulator in this process [24–26]. Oct-4 has been suggested as one
of four major factors that render the reprogramming capability of
adult cells into germline-competent-induced pluripotent stem cells
[31–33]. Previous studies also showed that mouse pulmonary stem
cells endogenously express Oct-4 [34]. Recently, Oct-4 transcript
can be consistently detected in human embryonal carcinomas,
testicular germ cell tumors, seminomas, and bladder carcinomas
[35–38]. The expression of Oct-4 has further been shown in
human breast cancer stem-like cells, suggesting that its expression
may be implicated in self-renewal and tumorigenesis via activating
its downstream target genes [39]. Herein we reported the isolation
of CD133-positive cells (LC-CD133
+) from clinical tissue samples
and lung cancer cell lines. LC-CD133
+ showed strong proliferative
and invasive capabilities in vitro and in vivo (Figs. 1, 2, and 3). LC-
CD133
+ also displayed significant resistance to chemotherapeutic
agents (Fig. 4). We also demonstrated that Oct-4 expression was
transcriptionally and translationally up-regulated in LC-CD133
+
(Fig. 5). Indeed, Oct-4 functions as a master switch during
differentiation by regulating the pluripotent potential in stem cells
[31–33]. Using the siRNA method with lentiviral vector for
knockdown of Oct-4 expression in LC-CD133
+, our data showed
that the treatment of Oct-4 siRNA can block the sphere formation
of LC-CD133
+ and further facilitate LC-CD133
+ to differentiate
into LC-CD133
2 (Fig. 5). Furthermore, in vivo animal studies
demonstrated the IHC of Oct-4 in the lung tumors of LC-
CD133
+-injected SCID mice were prominently up-regulated, and
the total lung tumor volume as well as Oct-4 IHC levels can be
significantly decreased in LC-CD133
+-injected mice by the
treatment of Oct-4 siRNA with or without chemoradiotherapy
(Fig. 7). In addition, we showed that increased incidence of Oct-4
expression correlated positively with the advanced stage of 78 lung
cancers (Figs. S1A–C). To our knowledge, this is the first study to
show that Oct-4 expression plays a crucial role in maintaining self-
renewal and cancer stem-like properties in LC-CD133
+.
The property of resistance to chemotherapy and irradiation
treatment is the major clinical criterion to characterize ‘‘cancer
stem-like cells (CSCs)’’ [6]. The existence of cancer stem-like cells
may explain why conventional anti-cancer therapies are able only
to suppress or shrink a tumor but often cannot completely
eradicate it, resulting in eventual recurrence [6,40,41]. Consistent
with these hypotheses, LC-CD133
+ were significantly resistant to
cisplatin, VP16 (eptoposide), doxorubicin, and paclitaxel than LC-
CD133
2 (p,0.001; Fig. 4). Even IR alone or a single chemodrug
can effectively inhibit cell growth of LC-CD133
2 (Fig. 4);
however, IR treatment combined with cisplatin and VP-16 still
failed to cause cell death in treated LC-CD133
+ (Fig. 4D). To
overcome resistance to radiotherapy and chemotherapy in LC-
CD133
+, treatment of Oct-4 siRNA was used and results showed
that the knockdown Oct-4 in LC-CD133
+ can significantly
improve the anti-cancer effect in single- or combination-treated
LC-CD133
+ in vitro and in vivo (Figs. 6 and 7). Moreover, the mean
survival rate of the LC-CD133
+ group can be significantly
prolonged after the treatment of Oct-4 siRNA with IR and
chemotherapy (Fig. 7). Recently, Oct-4 has been suggested to be a
protector for survival of ES cells from apoptosis induced by
etoposide, UV, or heat shock through the Stat3/Survivin pathway
[42]. Consistent with this important finding, our results suggest
that knockdown of Oct-4 expression can effectively enhance the
chemoradiosensitivity of LC-CD133
+ through activating the
apoptotic activities of caspase 3 and PARP (Fig. 6). Importantly,
Figure 3. Evaluation of the tumorigenicity of LC-CD133
+ and LC-CD133
2 in vivo. (A) The in vivo tumorigenicity of LC-CD133
+ and LC-
CD133
2 in tail vein-injected mice was analyzed by macroscopic and histological examination. A1–3: LC-CD133
2; arrows: normal alveolar structure of
lung. A4–6: LC-CD133
+; arrows: tumor formation. A7–9: LC-CD133
+; arrows: neovascularity and thrombosis. Bar: 200 mm. (B) The in vivo tumor-
restoration and proliferative ability of 10
4 LC-CD133
+,1 0
5 LC-CD133
2 and 5610
5 total tumor cells from patient No. 1, 2, 4, and 7 were examined by
xenotransplanted tumorigenicity analysis. (C) The tumor repopulation ability of LC-CD133
+ was studied in transplanted SCID mice. The expression
levels of CD133 were determined by FACS analysis from primary LC-CD133
+, second tumor, and third tumor. Data shown here are the mean6SD of
three experiments.
doi:10.1371/journal.pone.0002637.g003
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+ and LC-CD133
2. (A) Both 10,000 LC-CD133
+ and LC-CD133
2 were plated in a
96-well plate and treated with various concentrations of cisplatin, VP-16, doxorubicin, and paclitaxel for 24 hours in 10% FBS/DMEM/F-12 medium.
The survival rate was determined by MTT assay. (B) To determine the radiation effect on the tumor growth rate, an ionizing radiation (IR) dose from 0
to 10 Gy was used to treat LC-CD133
+ and LC-CD133
2.* p,0.01: LC-CD133
+ compared with LC-CD133
2. (C) The combined treatment effect of
radiochemotherapy in LC-CD133
+ and LC-CD133
2 were further evaluated. The four protocols—radiation (2 Gy) only, radiation with cisplatin (10 mM),
radiation with VP-16 (10 mM), and radiation with paclitaxel (10 nM)—were used. *p,0.01. Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g004
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PLoS ONE | www.plosone.org 9 July 2008 | Volume 3 | Issue 7 | e2637Figure 5. Up-regulated expressions of Oct-4 mRNA and protein in LC-CD133
+. (A) The amounts of Oct-4 transcripts of isolated LC-CD133
+
were significantly increased compared with those of LC-CD133
2 by real-time RT-PCR analyses. (B) Western blott data showed that the protein levels
of Oct-4 in LC-CD133
+ isolated from PLC and LLC were also significantly upregulated compared with those of LC-CD133
2. (C) The protein expression
of Oct-4 in LC-CD133
+ were effectively blocked by Oct-4 siRNA. Treatment of Oct-4 siRNA in LC-CD133
+ can impede the capabilities of SB formation
and further facilitate SB to differentiate into attached epithelial-like cells. Bar: 100 mm. (D) By using immunofluorescent staining, we showed that the
protein expression levels of both Oct-4 and CD133 in LC-CD133
+ were significantly diminished after Oct-4 siRNA treatment. Bar: 30 mm. (E) The
proportion of LC-CD133
2 were significantly increased in Oct-4 siRNA-treated LC-CD133
+ by FACS assay. *p,0.001. Data shown here are the
mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g005
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PLoS ONE | www.plosone.org 10 July 2008 | Volume 3 | Issue 7 | e2637Figure6.Evaluation ofthe chemoradiosensitivityand apoptotic activity in theknockdown Oct-4 expression ofLC-CD133
+. (A) Migratory
invasion ability and colony formation of LC-CD133
+ treated by Oct-4 siRNA was significantly decreased compared with non-Oct-4 siRNA-treated LC-
CD133
+ or LC-CD133
+ treated with scramble-siRNA (control; p,0.001). (B) The combined treatment effect of radiochemotherapy in non-Oct-4 siRNA-
treated LC-CD133
+, scramble-siRNA, and Oct-4 siRNA-treated LC-CD133
+ were further evaluated. Three groups of cells were exposed to IR (2 Gy) only or
radiation plus cisplatin. The cell survival rate was determined by MTT assay. After 72 hours of Oct-4 siRNA treatment, (C) the percentage of Annexin V-
positive cells and (D) the activities of caspase 3 (detected by ELISA assay) in Oct-4 siRNA-treated LC-CD133
+ were significantly increased. (D) The western
blotdatafurthershowedthatPARPwas significantly inducedinOct-4 siRNA-treatedLC-CD133
+when exposedtoIRalone,cisplatin alone,orIRcombined
with cisplatin. (*p,0.05: LC-CD133
+ with Oct-4 siRNA plus cisplatin vs. LC-CD133
+ with Oct-4 siRNA only. #p,0.05: LC-CD133
+ with Oct-4 siRNA plus
cisplatin and IR vs. LC-CD133
+ with Oct-4 siRNA plus IR). Bar: 50 mm. Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g006
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PLoS ONE | www.plosone.org 11 July 2008 | Volume 3 | Issue 7 | e2637Figure 7. Inhibition of tumorgeneic activity in Oct-4 siRNA-treated LC-CD133
+ with chemoradiotherapy. LC-CD133
+-GFP (10
4) cells of
different treatment groups were injected into the subcutaneous sites of nude mice. (A) The tumor volume and (B) The number of pulmonary tumor
nodules were significantly decreased in Oct-4 siRNA-treated LC-CD133
+ when exposed to IR alone, cisplatin alone, or IR combined with cisplatin. Cis:
cisplatin; Oct-4i: Oct-4 siRNA. (#p,0.01: LC-CD133
+ treated with Oct-4 siRNA vs. LC-CD133
+.* p,0.01: LC-CD133
+ treated with Oct-4 siRNA plus
cisplatin vs. LC-CD133
+ treated with cisplatin only. **p,0.01: LC-CD133
+ treated with Oct-4 siRNA plus IR vs. LC-CD133
+ treated with IR only.
##p,0.01: LC-CD133
+ treated with Oct-4 siRNA plus cisplatin and IR vs. LC-CD133
+ with Oct-4 siRNA plus IR). (C) The in vivo tumorgeneic activities of
LC-CD133
+- and LC-CD133
2-injected SCID mice were evaluated by histological review (left upper part). The expression levels of Oct-4 in the lung
lesions of LC-CD133
+-injected SCID mice with the different treatment protocol were studied by immunohistochemistry (IHC). The black arrows
indicate the positive signals for Oct-4 expression in the tumors detected by IHC. Bar: 50 mm. (D) Survival analysis of SCID mice injected by LC-CD133
+,
LC-CD133
+ treated with cisplatin, LC-CD133
+ treated with IR, and Oct-4 siRNA-treated LC-CD133
+ groups (IR alone, cisplatin alone, or IR combined
with cisplatin). Each group tested six mice (n=6). Data shown here are the mean6SD of three experiments.
doi:10.1371/journal.pone.0002637.g007
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the amount of Oct-4 in LC-CD133
+ (Fig. 7C) and in patients with
high-grade lung cancer (Fig. S1) is positively correlated with the
degree of resistance to chemoradiation therapy. Taken together,
these results indicate that the up-regulated expression of Oct-4 in
LC-CD133
+ may contribute to the development of chemora-
dioresistance in patients with lung cancer.
Recentstudies have revealed that thehuman ABCG2 transporter
is a P-glycoprotein that causes multidrug resistance (MDR)
including mitoxantrone, doxorubicin, and topoisomerase I inhib-
itors of irinotecan, topotecan, and 7-ethyl-10-hydroxycamptothecin
(topoisomerase inhibitor) and gefitinib (an inhibitor of EGF
receptor) in patients with lung cancer [41,43]. Hirschmann-Jax
and colleagues were the first to observe that ‘‘side population’’
cancer stem-like cells isolated from cell lines and patients with
neuroblastoma expressed high levels of ABCG2 and ABCG3
transporter genes as well as a greater capacity to expel cytotoxic
drugs [44]. Monzani and colleagues further showed that cancer
stem-like cells derived from the melanoma cell line highly co-
expressed CD133 and ABCG2 markers with enhanced tumorigenic
potential [45]. In this study, we found that LC-CD133
+ are highly
co-expressed with ABCG2 transporter and aresignificantly resistant
to conventional treatment methods compared with LC-CD133
2
(Figs. 2 & 4). Interestingly, a significant down-regulating of ABCG2
expression and an increase in the chemosensitivity of LC-CD133
+
were observed when the Oct-4 siRNA treatment was given (Data
not shown). Thus, more studies are needed to investigate whether
over-expressionof Oct-4, CD133,and/or ABCG2 play a role in the
development of MDR in LC-CD133
+ or surrogate markers of
therapeutic response in patients with lung cancer.
In conclusion, we demonstrated that LC-CD133
+ display a
higher Oct-4 expression with the ability to self-renew and may
represent a reservoir with unlimited proliferative potentials for
generating lung cancer cells. The resistance of LC-CD133
+ to in
vitro and in vivo chemoradiotherapy is partially due to preferential
activation of Oct-4 gene expression. In addition, these data
support that the up-regulated expressions of the Oct-4, self-
renewing gene of embryonic stem cells, play an important role in
the tumorigenicity of patients with lung cancer.
Supporting Information
Table S1
Found at: doi:10.1371/journal.pone.0002637.s001 (0.05 MB
DOC)
Figure S1 Correlation of Oct-4 expression levels and the clinical
grading and survival rate in the patients with lung cancers. (A)
Detection of Oct-4 expression in 78 NSCLC lung cancer patients
with different stages by using immunohistochemistry (IHC). Black
arrows: positive signals for Oct-4 by IHC. Bar: 50 um. (B) Oct-4
was detected in the almost high grades (III & IV) of lung cancer
tissues, and significantly expressed the higher intensity of Oct-4-
positive signals in grade III & IV (high grade) than those in grade I
& II (low grade) lung cancers patients (p,0.01). (C) Kaplan-Meier
analysis of overall survival in 78 lung cancer patients with or
without Oct-4 expression.
Found at: doi:10.1371/journal.pone.0002637.s002 (7.61 MB TIF)
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